Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth - PubMed (original) (raw)
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth
I M Harwerth et al. Br J Cancer. 1993 Dec.
Free PMC article
Abstract
Four monoclonal antibodies (MAbs) specific for the extracellular domain of the human erbB-2/HER2 protein (FRP5, FSP16, FWP51 and FSP77) have been isolated (Harwerth et al., J. Biol. Chem., 267, 15160-15167, 1992). In this paper we describe the effects of erbB-2 specific MAb administration on the tumorigenic growth of human erbB-2 transformed NIH3T3 cells implanted into athymic nude mice. Two antibodies, FWP51 and FSP77, inhibited the onset of tumour growth, while the administration of FRP5 and FSP16 did not affect tumour growth. In addition, administration of MAbs FWP51 and FSP77 led to a retardation in the growth of established tumours. Treatment was not curative in that tumours regrew within two weeks of the final treatment. The administration of a combination of MAbs FWP51 and FSP77 which react with two distinct regions on the erbB-2 molecule was more effective than treatment with either MAb alone. The two growth-inhibitory antibodies were also effective in the treatment of tumours established from SKOV3 cells, a human ovarian tumour cell line with high levels of the erbB-2 protein. The effect of the MAbs on the anchorage-independent growth of erbB-2 transformed cells and on erbB-2 receptor turnover was also measured.
Similar articles
- Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists.
Harwerth IM, Wels W, Marte BM, Hynes NE. Harwerth IM, et al. J Biol Chem. 1992 Jul 25;267(21):15160-7. J Biol Chem. 1992. PMID: 1353079 - Immunotherapy of human tumour xenografts overexpressing the EGF receptor with rat antibodies that block growth factor-receptor interaction.
Modjtahedi H, Eccles S, Box G, Styles J, Dean C. Modjtahedi H, et al. Br J Cancer. 1993 Feb;67(2):254-61. doi: 10.1038/bjc.1993.49. Br J Cancer. 1993. PMID: 7679281 Free PMC article. - The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468.
Modjtahedi H, Styles JM, Dean CJ. Modjtahedi H, et al. Br J Cancer. 1993 Feb;67(2):247-53. doi: 10.1038/bjc.1993.48. Br J Cancer. 1993. PMID: 8094290 Free PMC article. - Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer.
Bast RC Jr, Xu F, Yu Y, Crews J, Argon Y, Maier L, Lidor Y, Berchuck A, Boyer CM. Bast RC Jr, et al. Immunol Ser. 1994;61:23-30. Immunol Ser. 1994. PMID: 7912111 Review. No abstract available. - The epidermal growth factor receptor as a target for therapy in breast carcinoma.
Baselga J, Mendelsohn J. Baselga J, et al. Breast Cancer Res Treat. 1994 Jan;29(1):127-38. doi: 10.1007/BF00666188. Breast Cancer Res Treat. 1994. PMID: 8018961 Review.
Cited by
- Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance.
Waks AG, Martínez-Sáez O, Tarantino P, Braso-Maristany F, Pascual T, Cortés J, Tolaney SM, Prat A. Waks AG, et al. Nat Rev Clin Oncol. 2024 Nov;21(11):818-832. doi: 10.1038/s41571-024-00939-2. Epub 2024 Sep 13. Nat Rev Clin Oncol. 2024. PMID: 39271787 Review. - Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics-The Tale of HER2.
Leyton JV. Leyton JV. Antibodies (Basel). 2020 Jul 13;9(3):32. doi: 10.3390/antib9030032. Antibodies (Basel). 2020. PMID: 32668710 Free PMC article. Review. - Differential Effects of Inhibitory and Stimulatory Anti-HER2 Monoclonal Antibodies on AKT/ERK Signaling Pathways.
Soltantoyeh T, Bahadori T, Hosseini-Ghatar R, Khoshnoodi J, Roohi A, Mobini M, Golsaz-Shirazi F, Jeddi-Tehrani M, Amiri MM, Shokri F. Soltantoyeh T, et al. Asian Pac J Cancer Prev. 2018 Aug 24;19(8):2255-2262. doi: 10.22034/APJCP.2018.19.8.2255. Asian Pac J Cancer Prev. 2018. PMID: 30139234 Free PMC article. - Precision Medicine in Hormone Receptor-Positive Breast Cancer.
Nasrazadani A, Thomas RA, Oesterreich S, Lee AV. Nasrazadani A, et al. Front Oncol. 2018 May 4;8:144. doi: 10.3389/fonc.2018.00144. eCollection 2018. Front Oncol. 2018. PMID: 29780747 Free PMC article. Review. - Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.
Chang HR, Park HS, Ahn YZ, Nam S, Jung HR, Park S, Lee SJ, Balch C, Powis G, Ku JL, Kim YH. Chang HR, et al. BMC Cancer. 2016 Mar 9;16:200. doi: 10.1186/s12885-016-2232-2. BMC Cancer. 2016. PMID: 26955870 Free PMC article.
References
- Nature. 1984 Dec 6-12;312(5994):513-6 - PubMed
- J Biol Chem. 1992 Jul 25;267(21):15160-7 - PubMed
- Science. 1985 Dec 6;230(4730):1132-9 - PubMed
- Nature. 1986 Jan 16-22;319(6050):230-4 - PubMed
- Biotechnology (N Y). 1992 Oct;10(10):1128-32 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous